Alzprotect, a French biopharmaceutical company, has successfully completed the open-label extension (OLE) phase following its Phase 2a clinical trial of AZP2006 (ezeprogind®), a treatment for Progressive Supranuclear Palsy (PSP). The…
The report titled “CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027” has been added to ResearchAndMarkets.com’s offerings. CD137, also known as 4-1BB, has emerged as a promising target in…
Wedgewood Pharmacy has officially added molnupiravir to its formulary, offering a new option for the treatment of Feline Infectious Peritonitis (FIP). Originally developed to treat viral infections in humans, including…
Viatris Inc. (NASDAQ: VTRS, “Viatris” or the “Company”) today announced the early results of its subsidiary Utah Acquisition Sub Inc.’s (“UAS”) previously announced cash tender offer (the “Maximum Tender Offer”).…
Blue Cross and Blue Shield of Alabama is dedicated to ensuring its members receive high-quality, affordable care through cost-effective healthcare providers. Starting December 1, 2024, Labcorp, a leader in comprehensive…
Zoetis Inc., the leading global animal health company, is set to launch its new Vetscan OptiCell™ hematology analyzer, a cutting-edge diagnostic tool that combines cartridge-based technology with AI-powered capabilities for…
Novartis announced today that the US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS)…
Massive Bio Launches Patient Connect: A Revolutionary Platform for Global Cancer Clinical Trial Access Massive Bio, a global frontrunner in AI-driven cancer clinical trial enrollment, has unveiled Patient Connect, a…
Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, has announced new findings from a study using its Cellworks Platform to predict homologous recombination deficiency…
PharmaLegacy Laboratories, a leading provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO). This acquisition marks…
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), an AI-driven biotherapeutics research and technology company, has announced its financial results for the first quarter of fiscal 2025, ending on July 31, 2024. All…